BI calls it quits in hep. C

Share this article:

Boeheringer Ingelheim is officially out of the hepatitis C space. The Connecticut drugmaker announced Friday that it was killing its faldaprevir interferon-based regimen because “there is no longer an unmet medical need” for this treatment.

The company hinted at such a move in April when it said Phase III results of its faldaprevir-deleobuvir combination “did not live up to expectations,” and that these results were prompting the firm to examine “its activities in the field of hepatitis C therapy in depth.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters